ST

Solvonis Therapeutics

Organization

Heard in 2 episodes across 1 show since Aug 2026

A UK-listed biopharmaceutical company developing medicines in areas including mental health and central nervous system disorders, with esketamine-related programmes among its priorities.

Episodes

2
across 1 show

First heard

Aug 2026

Expert statements

11
10 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20261
Sep 20260
Oct 20260
Nov 20261

Email alert

Email me when Solvonis Therapeutics comes up on a podcast

One email a week at most, with the new episodes that mention Solvonis Therapeutics. Free, no account needed, unsubscribe in one click.

What experts have said about Solvonis Therapeutics

11 statements · 10 positive · 1 neutral

  1. Solvonis would need Phase 2 completion and Phase 3 entry to match Transcend’s deal stage.

    “We would need to complete a Phase 2 programme and be in Phase 3 to be at exactly the same stage as Transcend was”

    Listen at 3:19

    Open the episode · S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
  2. Anthony TennysonPositiveNov 5, 2026· The Sunday Roast

    Solvonis is materially undervalued versus US psychedelic-sector peers.

    “We are materially undervalued compared to them”

    Listen at 5:27

    Open the episode · S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
  3. Anthony TennysonPositiveNov 5, 2026· The Sunday Roast

    Tennyson expects progress on Solvonis programs and regulatory feedback within two to four months.

    “That is what I have confidence over in the next two to four months”

    Listen at 10:06

    Open the episode · S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Solvonis Therapeutics, newest first